Sign in
Explore the registryTrack Olaparib continuous 300 mg bd.'s trials

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

Olaparib Continuous (28-Day cycle) 300 mg BD.OngoingActive not recruitingPhase 2Open NCT03330847 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

NCT03330847 · Trial Tracker · ComplyRx